Ethinyl estradiol and norgestimate and Oncaspar
Determining the interaction of Ethinyl estradiol and norgestimate and Oncaspar and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance. MANAGEMENT: The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.
Professional:GENERALLY AVOID: Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance.
MANAGEMENT: The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.
Generic Name: ethinyl estradiol / norgestimate
Brand name: Estarylla, Femynor, Mono-Linyah, Mononessa, Ortho Tri-Cyclen, Previfem, Sprintec, Tri-Lo-Marzia, TriNessa, Ortho Tri-Cyclen, Ortho-Cyclen, Sprintec 28, Tri-Lo-Marzia>
Synonyms: Ethinyl Estradiol and Norgestimate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ethinyl estradiol and norgestimate-Oncovin
- Ethinyl estradiol and norgestimate-Ondansetron
- Ethinyl estradiol and norgestimate-Ondansetron and Dextrose
- Ethinyl estradiol and norgestimate-Ondansetron Hydrochloride
- Ethinyl estradiol and norgestimate-Ondansetron injection
- Ethinyl estradiol and norgestimate-Ondansetron ODT
- Oncaspar-Ethinyl estradiol and norgestrel
- Oncaspar-Ethinyl estradiol and segesterone vaginal ring
- Oncaspar-Ethinyl Estradiol, Drospirenone, and Levomefolate
- Oncaspar-Ethinyl estradiol, folic acid, and levonorgestrel
- Oncaspar-Ethinyl Estradiol, Norethindrone, and Ferrous Fumarate
- Oncaspar-Ethiodized oil Injection